.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Chubb
Covington
AstraZeneca
Chinese Patent Office
Queensland Health
Johnson and Johnson
Novartis
Farmers Insurance
Deloitte

Generated: September 24, 2017

DrugPatentWatch Database Preview

MEXATE Drug Profile

« Back to Dashboard

What is the patent landscape for Mexate, and what generic Mexate alternatives are available?

Mexate is a drug marketed by Bristol, Bristol Myers, and Bristol Myers Squibb. and is included in three NDAs.

The generic ingredient in MEXATE is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.

Summary for Tradename: MEXATE

Patents:0
Applicants:3
NDAs:3
Bulk Api Vendors: see list90
Clinical Trials: see list78
Patent Applications: see list9,363
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEXATE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol
MEXATE
methotrexate sodium
INJECTABLE;INJECTION086358-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol
MEXATE
methotrexate sodium
INJECTABLE;INJECTION086358-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol
MEXATE
methotrexate sodium
INJECTABLE;INJECTION086358-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol
MEXATE
methotrexate sodium
INJECTABLE;INJECTION086358-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
MEXATE-AQ PRESERVED
methotrexate sodium
INJECTABLE;INJECTION089887-001Apr 14, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers
MEXATE-AQ
methotrexate sodium
INJECTABLE;INJECTION088760-001Feb 14, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
US Department of Justice
Medtronic
Harvard Business School
Cipla
Julphar
Colorcon
Baxter
AstraZeneca
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot